Related Experiment Video
Updated: May 27, 2026

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
Published on: July 3, 2020
PlexinA2 mediates osteoblast differentiation via regulation of Runx2
Ji-Eun Oh1, Hyung Joon Kim, Woo-Shin Kim
1Department of Cell and Developmental Biology, BK21 and DRI, Seoul National University School of Dentistry, Seoul, Korea.
Abstract:
The imbalance between bone-resorbing osteoclasts and bone-forming osteoblasts often leads to bone destructive diseases such as osteoporosis. In contrast to the development of several antiresorptive agents for osteoporosis therapy, discovery of anabolic drugs has been difficult because of an insufficient understanding of the complex mechanism of bone formation. In a microarray analysis with mouse preosteoblast cells, we found that PlexinA2 (PlxnA2), a molecule previously known to mediate axon guidance in neural development, was upregulated by the osteogenic factor BMP2. PlxnA2-specific siRNA decreased Runx2 expression, osteoblast differentiation, and mineralization. Runx2 overexpression restored osteoblastic differentiation of PlxnA2-knockdown cells. PlxnA2 was associated with both type 1 and 2 BMP receptors, and BMP2 increased the interaction between PlxnA2 and type 1 receptors. PlxnA2 also affected Smad and Akt signaling pathways downstream of BMP2. Taken together, the results of our study reveal that PlxnA2 has a pro-osteogenic function by modulating BMP2 signaling. Therefore, PlxnA2 may be a useful target for development of bone anabolic therapeutics.
Insights
PlexinA2 (PlxnA2) promotes bone formation by enhancing BMP2 signaling in osteoblasts. This discovery offers a potential new target for developing bone anabolic therapeutics to treat diseases like osteoporosis.
Area of Science:
- Bone biology
- Cell signaling
- Molecular medicine
Background:
- Osteoporosis and other bone diseases result from an imbalance between bone resorption and formation.
- Developing anabolic drugs for bone formation is challenging due to incomplete understanding of the underlying mechanisms.
Purpose of the Study:
- To investigate the role of PlexinA2 (PlxnA2) in bone formation.
- To explore PlxnA2's potential as a therapeutic target for bone anabolic treatments.
Main Methods:
- Microarray analysis of mouse preosteoblast cells treated with BMP2.
- Use of PlxnA2-specific siRNA to assess gene expression and cell differentiation.
- Investigation of PlxnA2 interactions with BMP receptors and downstream signaling pathways (Smad, Akt).
Main Results:
- PlexinA2 (PlxnA2) expression is upregulated by BMP2 in preosteoblasts.
- PlxnA2 knockdown reduces Runx2 expression, osteoblast differentiation, and mineralization.
- PlxnA2 interacts with BMP type 1 and 2 receptors, modulating BMP2 signaling pathways.
Conclusions:
- PlexinA2 (PlxnA2) exhibits a pro-osteogenic function by mediating BMP2 signaling.
- PlxnA2 represents a promising target for novel bone anabolic therapeutics.
Related Concept Videos
Master Transcription Regulators
RNA Polymerase II Accessory Proteins
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Osteoclasts in Bone Remodeling
Regulation of Expression at Multiple Steps
Regulation of Expression Occurs at Multiple Steps
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...
